BioSpace News Archive

A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today

Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger, Nuvo’s President & Chief Executive Officer

Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that new data from its most advanced gene therapy programs will be presented at the WMS25 Virtual Congress, the 25th International Annual Congress of the World Muscle Society, being held Sept. 28 – Oct. 2.

GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.da

Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced the publication of an abstract for an electron

Kenergy Scientific, Inc. is pleased to announce MedSmart Group, Inc’s, subsidiary MedSmart Men’s Wellness and Antiaging centers is focused on Men’s health, and well-being.

- ONGENTYS, the First and Only FDA-Approved Once-Daily COMT Inhibitor, Decreases “Off” Time and Increases “On” Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa - FDA Approval of ONGENTYS Supported by Data from 38 Clinical Studies, Including Two Multinational Phase III Clinical Studies (BIPARK-1 and BIPARK-2), with More Than 1,000 Parkinson’s Disease Patients Treated with ONGENTYS [14-S

Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, 2020.